share_log

RedChip Interviews Inspira Technologies' CFO Joe Hayon

RedChip Interviews Inspira Technologies' CFO Joe Hayon

紅籌公司採訪Inspira技術公司首席財務官喬·海恩
Accesswire ·  2022/06/30 09:05

ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Companies will air a new C-Level interview with Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies") on The RedChip Money Report® on Bloomberg TV, this Saturday, July 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

佛羅裏達州奧蘭多/ACCESSWIRE/2022年6月30日/紅籌公司將於本週六,7月2日晚7點在彭博電視臺播出對Inspira Technologies Oxy B.H.N.Ltd.(納斯達克代碼:IINN)(納斯達克代碼:IINNW)(以下簡稱“公司”或“Inspira科技公司”)的新一輪C級訪談。東部時間(ET)。據估計,全美約有7300萬個家庭可以收看彭博電視。

RedChip's CEO Dave Gentry interviews Inspira™ Technologies' CFO Joe Hayon in this exclusive interview, covering the questions on the mind of current and future shareholders.

紅籌公司首席執行官戴夫·金特里在這次獨家專訪中採訪了Inspira™技術公司的首席財務官喬·海恩,涵蓋了當前和未來股東心中的問題。

Access this interview in its entirety at

訪問此訪談全文,請訪問

Inspira™ Technologies is redefining artificial respiration with its breakthrough Augmented Respiration Technology (ART) system, a minimally invasive, scalable and cost-effective early-stage respiratory support system that is designed to utilize direct blood oxygenation in awake patients, rebalancing oxygen saturation levels in minutes in order to minimize the need for intubation, induced coma, and invasive mechanical ventilation treatment.

Inspira™科技公司正在重新定義人工呼吸,其突破性的增強呼吸技術(ART)系統是一種微創、可擴展且經濟高效的早期呼吸支持系統,旨在利用清醒患者的直接血液氧合,在幾分鐘內重新平衡氧飽和度水平,以最大限度地減少插管、誘導昏迷和侵入性機械通氣治療的需要。

Inspira Technologies is targeting the millions of acute respiratory failure patients each year for treatment with the ART™ system¹. The Company's go-to-market strategy includes aiming to establish multiple recurring revenue streams across medical sectors and markets.

Inspira科技公司針對每年數以百萬計的急性呼吸衰竭患者使用ART™系統?進行治療。該公司的入市戰略包括致力於在醫療部門和市場建立多種經常性收入流。

The ART's design supports the Company's strategic business model to encourage the extension of acute respiratory care beyond the ICU and into General Medical Units. Inspira Technologies is actively pursuing regulatory approvals in the U.S. (primary) and Europe (secondary) and is targeting up to $401 million in potential sales through its existing, and previously announced, agreements. The Company's pipeline is anticipated to continue to grow as it pursues collaborations with leading hospitals and professional associations for regional deployments. Additional opportunities for value creation include collaborations with strategic partners, such as global medical device companies and multinational electronics contract manufacturers, which may acquire primary components of the ART.

ART的設計支持該公司的戰略商業模式,鼓勵將急性呼吸護理擴展到ICU以外的普通醫療單位。Inspira技術公司正在積極尋求美國(主要)和歐洲(次要)監管機構的批准,並計劃通過其現有的和之前宣佈的協議,實現高達4.01億美元的潛在銷售額。隨着該公司尋求與領先醫院和專業協會合作進行地區性部署,該公司的渠道預計將繼續增長。其他創造價值的機會包括與戰略合作伙伴的合作,例如全球醫療設備公司和跨國電子產品合同製造商,它們可能會收購ART的主要組成部分。

Interview highlights:

採訪亮點:

In the exclusive RedChip Money Report interview, Hayon discusses the Company's potentially game-changing technology, acute respiratory failure patient market statistics, FDA approval plans, and much more.

在RedChip Money Report獨家訪談中,Hayon討論了該公司可能改變遊戲規則的技術、急性呼吸衰竭患者市場統計數據、FDA批准計劃等。

Access this interview in its entirety at

訪問此訪談全文,請訪問

About The RedChip Money Report®

關於紅籌資金報告®

The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

紅籌資金報告®由紅籌公司製作,該公司是一家國際投資者關係和媒體公司,擁有30年的經驗,專注於今天發現明天的藍籌股™.《紅籌資金報告》(The RedChip Money Report®)提供了關於小盤股投資的精闢評論、華爾街分析師的採訪、金融書評以及對上市公司高管的專題採訪。

About Inspira™ Technologies

關於Inspira™技術

Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (ART), designed to rebalance patient oxygen saturation levels. The Company's ART technology potentially allows patients to remain awake during treatment while minimizing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's product has not yet been tested or used in humans and has not been approved by any regulatory entity.

Inspira Technologies是一家在呼吸治療領域創新的醫療技術公司。該公司開發了一種突破性的增強呼吸技術(ART),旨在重新平衡患者的血氧飽和度水平。該公司的ART技術有可能使患者在治療期間保持清醒,同時最大限度地減少對需要插管和藥物誘導昏迷的高度侵入性、高風險和昂貴的機械通風系統的需求。該公司的產品尚未在人體上進行測試或使用,也未獲得任何監管實體的批准。

For more information, please visit our corporate website:

欲瞭解更多信息,請訪問我們的公司網站:

About RedChip Companies

關於紅籌公司

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

紅籌公司是一家擁有5000美元股份的公司,是一家專注於微市值和小盤股公司的國際投資者關係、媒體和研究公司。30年來,紅籌為客户提供了具體、可衡量的結果。我們的時事通訊《紅籌資金報告》每週在線發送給60,000名投資者。紅籌為小盤股和小盤股公司開發了業內最全面的服務平臺。這些服務包括:其股票研究的全球分銷網絡;在美國主要城市的零售和機構路演;面向股票經紀人、RIA、機構和家族理財室的對外營銷;已產生數百萬獨特投資者觀點的數字媒體投資者關係平臺;投資者網絡研討會和團體電話會議;每週在彭博美國播出的電視節目“紅籌資金報告”;本地和全國市場的電視廣告;企業和產品視頻;網站設計;以及傳統投資者關係服務,其中包括新聞稿撰寫、投資者演示文稿的開發、季度電話會議腳本編寫、戰略諮詢、融資等。

To learn more about RedChip's products and services, please visit:

要了解更多有關紅籌公司產品和服務的信息,請訪問:

"Discovering Tomorrow's Blue Chips Today"™

《今日發現明天的藍籌股》™

Forward Looking Statements

前瞻性陳述

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company is using forward-looking statements when it discusses its goals and that Yeheskely-Hayon's experience the field of blood oxygenation and ECMO devices will contribute to the development of the Company's ART system. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Registration Statement on Form F-1 filed with the SEC, as well as its subsequent public filings, which are available on the SEC's website, www.sec.gov.

本新聞稿包含符合美國聯邦證券法的明示或暗示的前瞻性陳述。例如,該公司在討論其目標時使用前瞻性陳述,耶斯凱利-海恩在血液氧合和ECMO設備領域的經驗將有助於公司ART系統的發展。這些前瞻性陳述及其影響僅基於公司管理層目前的預期,受許多因素和不確定因素的影響,這些因素和不確定性可能導致實際結果與前瞻性陳述中所描述的大不相同。除非法律另有要求,否則公司沒有義務公開發布對這些前瞻性陳述的任何修訂,以反映本前瞻性陳述之後發生的事件或情況,或反映意外事件的發生。有關影響公司的風險和不確定因素的更詳細信息,請參見公司提交給美國證券交易委員會的F-1表格註冊説明書中的“風險因素”標題以及公司隨後提交的公開文件,這些文件可在美國證券交易委員會的網站www.sec.gov上查閲。

Contact:

聯繫方式:

Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
IINN@redchip.com

戴夫·金特里
紅籌公司。
1-800-紅籌(733-2447)
或407-491-4498
郵箱:iinn@redchip.com

--END--

--完

SOURCE: RedChip

資料來源:紅籌公司


View source version on accesswire.com:
在accesswire.com上查看源代碼版本:

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論